Ani Pharmaceuticals Inc (ANIP) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Ani Pharmaceuticals reported revenue of $883.4M, up 43.8% from $614.4M the year before. Net income was $78.3M (a 8.9% net margin), or $3.32 per diluted share. Gross margin was 12.6% and operating margin was 12.6%. Operating activities generated $185.2M of cash, leaving $171.4M of free cash flow. At fiscal year end, Ani Pharmaceuticals held $1.44B in total assets against $899.7M in total liabilities, including $285.6M of cash and equivalents.
Open the full interactive Ani Pharmaceuticals financials → Quarterly statements, key ratios, valuation history and price charts.
Ani Pharmaceuticals Key Stats
| Share Price | $70.84 |
|---|---|
| Market Cap | $1.55B |
| P/E Ratio | 21.3 |
| Dividend Yield | 0.02% |
| Revenue YoY Growth | +43.8% |
| 52-Week Range | $70.19 – $95.38 |
| Shares Outstanding | 21.2 million (basic, 2026 Q2) |
Ani Pharmaceuticals Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $208.5M | $216.1M | $316.4M | $486.8M | $614.4M | $883.4M |
| Cost of Goods Sold | $224.5M | $255.9M | $351.7M | $439.8M | $613.8M | $772.3M |
| Gross Profit | $121.3M | -$39.8M | -$35.3M | $47.0M | $584,000 | $111.1M |
| Operating Income | -$16.0M | -$39.8M | -$35.3M | $47.0M | $584,000 | $111.1M |
| Pre-Tax Income | -$26.0M | -$56.1M | -$62.7M | $19.9M | -$22.2M | $95.8M |
| Income Tax | -$3.4M | -$13.5M | -$14.8M | $1.1M | -$3.7M | $17.5M |
| Net Income | -$22.5M | -$42.6M | -$47.9M | $18.8M | -$18.5M | $78.3M |
| Diluted EPS | -$1.88 | -$3.40 | -$3.05 | $0.85 | -$1.04 | $3.32 |
Ani Pharmaceuticals Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $227.8M | $247.1M | $237.5M | $266.0M |
| Net Income | $26.6M | $27.5M | $29.5M | $24.7M |
| Diluted EPS | $1.13 | $1.29 | $1.28 | $1.05 |
Ani Pharmaceuticals Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $7.9M | $100.3M | $48.2M | $221.1M | $144.9M | $285.6M |
| Current Assets | $170.3M | $321.8M | $344.3M | $519.8M | $527.7M | $753.1M |
| Total Assets | $461.2M | $771.6M | $760.1M | $904.4M | $1.28B | $1.44B |
| Current Liabilities | $78.6M | $87.5M | $99.4M | $145.5M | $193.7M | $278.1M |
| Total Long-Term Debt | $185.7M | $287.4M | $286.5M | $285.7M | $318.3M | $309.1M |
| Total Liabilities | $265.5M | $412.9M | $421.5M | $446.8M | $855.2M | $899.7M |
| Shareholders' Equity | $195.7M | $333.9M | $313.7M | $432.7M | $403.7M | $540.7M |
Ani Pharmaceuticals Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | $15.3M | $3.3M | -$31.2M | $119.0M | $64.0M | $185.2M |
| Cash From Investing | -$68.3M | -$105.5M | -$15.7M | -$18.5M | -$404.7M | -$34.3M |
| Cash From Financing | -$1.4M | $194.6M | -$5.1M | $67.4M | $264.9M | -$9.9M |
| Free Cash Flow | $9.1M | $765,000 | -$40.1M | $110.1M | $47.8M | $171.4M |
| Dividends Paid | — | $190,000 | $1.6M | $1.6M | $1.6M | $1.2M |
Figures from Ani Pharmaceuticals' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Ani Pharmaceuticals financials page for every line item.
Ani Pharmaceuticals Company Profile
| Ticker | ANIP |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Princeton, New Jersey |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001023024 |
Frequently Asked Questions
What was Ani Pharmaceuticals' revenue in fiscal 2025?
Ani Pharmaceuticals (ANIP) reported revenue of $883.4M for fiscal 2025.
What is Ani Pharmaceuticals' annual revenue history?
Ani Pharmaceuticals' annual revenue by fiscal year: 2020: $208.5M; 2021: $216.1M; 2022: $316.4M; 2023: $486.8M; 2024: $614.4M; 2025: $883.4M.
What was Ani Pharmaceuticals' net income in fiscal 2025?
Ani Pharmaceuticals reported net income of $78.3M for fiscal 2025.
What was Ani Pharmaceuticals' earnings per share (EPS) in fiscal 2025?
Ani Pharmaceuticals' diluted EPS was $3.32 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Ani Pharmaceuticals generate in fiscal 2025?
Ani Pharmaceuticals generated $171.4M of free cash flow in fiscal 2025.
What was Ani Pharmaceuticals' revenue last quarter?
In its most recent reported quarter (2026 Q2), Ani Pharmaceuticals reported revenue of $266.0M.
How much debt does Ani Pharmaceuticals have?
Ani Pharmaceuticals reported $309.1M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Ani Pharmaceuticals are outstanding?
Ani Pharmaceuticals reported a weighted average of 21.2 million basic shares outstanding in 2026 Q2.
What is Ani Pharmaceuticals' market cap?
Based on its latest closing price, Ani Pharmaceuticals (ANIP) has a market capitalization of about $1.55B.
When does Ani Pharmaceuticals' fiscal year end?
Ani Pharmaceuticals' fiscal year end, as registered with the SEC, is December 31.
Where is Ani Pharmaceuticals headquartered?
Ani Pharmaceuticals lists its business address in Princeton, New Jersey in its SEC filings.